Free Trial

Eli Lilly and Company $LLY Stock Acquired by Bessemer Group Inc.

Eli Lilly and Company logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Bessemer Group increased its Eli Lilly stake by 7.8% in the third quarter, adding 72,133 shares to hold nearly 996,000 shares worth about $1.15 billion. Institutional investors and hedge funds own 82.53% of the stock.
  • Lilly reported quarterly earnings of $7.48 per share, beating estimates of $5.71, while revenue rose 38.6% year over year to $24.40 billion.
  • Analyst sentiment is broadly positive: the stock has a “Moderate Buy” consensus and a consensus price target of $1,416.64, though China Merchants Securities downgraded it to “Hold.”
  • Five stocks we like better than Eli Lilly and Company.

Bessemer Group Inc. boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 7.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 995,948 shares of the company's stock after purchasing an additional 72,133 shares during the quarter. Eli Lilly and Company comprises 1.6% of Bessemer Group Inc.'s holdings, making the stock its 9th largest holding. Bessemer Group Inc. owned 0.11% of Eli Lilly and Company worth $1,152,391,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in LLY. BlackRock Inc. boosted its holdings in Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares in the last quarter. State Street Corp grew its stake in Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company's stock valued at $43,438,262,000 after acquiring an additional 605,752 shares during the period. Bank of America Corp DE bought a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Eli Lilly and Company by 1.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock valued at $8,647,153,000 after acquiring an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC increased its holdings in shares of Eli Lilly and Company by 7.9% during the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock valued at $6,550,587,000 after acquiring an additional 400,538 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research reports. Cantor Fitzgerald upped their target price on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the stock an "overweight" rating in a research report on Monday, November 2nd. China Merchants Securities downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday. UBS Group raised their price objective on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a "buy" rating in a research note on Friday, October 30th. Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the company an "overweight" rating in a report on Friday, October 30th. Finally, Citigroup boosted their target price on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a "buy" rating in a research report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $1,416.64.

View Our Latest Stock Analysis on LLY

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares of the company's stock, valued at $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Trading Up 0.0%

NYSE LLY opened at $1,444.05 on Monday. The stock has a market capitalization of $1.36 trillion, a price-to-earnings ratio of 46.87, a PEG ratio of 1.73 and a beta of 0.40. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,460.00. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The business's fifty day moving average is $1,242.25 and its 200-day moving average is $1,110.30.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm's revenue for the quarter was up 38.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $7.02 earnings per share. Equities research analysts predict that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company's dividend payout ratio is 22.46%.

Key Stories Impacting Eli Lilly and Company

Here are a few of the latest stories about LLY:

  • Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania manufacturing facility intended to make next-generation obesity medicines, including investigational retatrutide. The project supports the company’s broader production expansion, although the site is not expected to begin operations until 2031. Lilly announces Pennsylvania manufacturing facility
  • Positive Sentiment: Hims & Hers will offer Lilly’s FDA-approved Zepbound and Foundayo, potentially extending patient reach through another care platform. Separately, exchange-traded funds were reported to have added to their Lilly holdings, signaling investor demand. Hims partners with Lilly to offer weight-loss drugs
  • Negative Sentiment: China Merchants Securities downgraded Lilly from “buy” to “hold,” providing a cautionary view amid the positive product and capacity news. China Merchants Securities stock recommendations

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

See Also

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Eli Lilly and Company Right Now?

Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines